No Detail Found!

In vitro synergistic activity of ceftazidime-avibactam and aztreonam against new delhi metallo-β-lactamase- producing clinical enterobacterales isolates

Author(s)
Naif Fahd AlAnazi Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University Medical City, Riyadh - Saudi Arabia ; Department of Pathology & Laboratory Medicine, King Khalid University Hospital, King Saud University Medical City, King Saud University, Riyadh - Saudi Arabia
Mohammad Marie Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University Medical City, Riyadh - Saudi Arabia
Ali Mohammad Somily Department of Pathology, College of Medicine, King Saud University, Riyadh - Saudi Arabia; King Saud University Medical City, King Saud University, Riyadh - Saudi Arabia
Khalifa Binkhamis Department of Pathology, College of Medicine, King Saud University, Riyadh - Saudi Arabia ; King Saud University Medical City, King Saud University, Riyadh - Saudi Arabia
Muhammad Arshad Canberra, Australian Capital Territory - Australia ; Department of Pathology and Laboratory Medicine, King Abdulaziz Hospital, Ministry of National Guard Health Affairs, AlAhsa - Saudi Arabia
Akram A. Alfuraydi Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University Medical City,Riyadh , Saudi Arabia
Muhammad Absar Department of Pathology and Laboratory Medicine, King Abdulaziz Hospital, Ministry of National Guard Health Affairs, AlAhsa , Saudi Arabia
Abstract
Background: Carbapenemase-producing-Enterobacterales (CPE) infections are on the rise and associated with increased morbidity and mortality, due to a limited number of therapeutic options. The goal of this study was to assess the synergistic activity of ceftazidime-avibactam (CZA) and aztreonam (ATM) combination against phenotypically and genetically characterized blaMBL-producing Enterobacterales. Methods: In this study, forty (n=40) non-repeat, CPE clinical isolates, including: n=35 Klebsiella pneumoniae, n=2 each of Escherichia coli and Klebsiella oxytoca, and n=1 Enterobacter cloacae isolates were identified and susceptibilities were assessed using the Vitek-II compact (bioMérieux, Inc., France) and Microscan Walkaway (Beckman Coulter) systems. Genotypic analysis of clinically relevant carbapenemases was performed by using Xpert-Carba-R assay on GeneXpert (Cepheid, USA). The minimum inhibitory concentrations (MICs) and synergy testing of CZA and ATM, were tested by the Etest fixed ratio method (bioMérieux, Inc., France). The fractional inhibitory concentration index (FICI) was calculated for each antibiotic. Results: Our results showed that 97.5% of blaMBL-producing Enterobacterales isolates were susceptible to an in-vitro CZA + ATM combination regimen. The fractional inhibitory concentration index (FICI) ranged from 0.001 to 1.001. Among the tested CPE isolates, Synergy was observed in 36/40 (90%), an additive effect was observed in 5% (n=2)’ while two (5%) isolates showed indifference. There was no antagonism observed in our study. Conclusion: Our study exhibited a potent activity of CZA and ATM combination synergy against clinical CPE metallo- ß-lactamase producers. More extensive studies involving a variety of Gram-negative pathogens with different resistance mechanisms are required to determine the efficacy of this combination regimen.
Publication Details
Page(s) 871-877
DOI DOI not available
Published Journal: Advancements in life sciences, Volume: 11, Issue: 4, Year: 2024

Request the full text from PASTIC

Keywords
synergy, Aztreonam Ceftazidime-Avibactam, Carbapenem-Resistant Enterobacterales, Etest
References
Jean SS,Gould IM,Lee WS,Hsueh PR .2019 .New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship. , 79 : 705-714.
Wang B,Pan F,Wang C,Zhao W,Sun Y .2020 .Molecular epidemiology of Carbapenem-resistant Klebsiella pneumoniae in a paediatric hospital in China. International Journal of Infectious Diseases, 93 : 311-319.
Carbapenem-Resistant Enterobacteriaceae Alotaibi F. .2019 .An update narrative review from Saudi Arabia. Journal of Infection and Public Health, 12(4) : 465-471.
Lee CR,Lee JH,Park KS,Kim YB,Jeong BC,Methods Detection .2016 .Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options,. , 7 : 895.
Wang Z,Ma K,Chen Z,Guo Z,Zhao G .2020 .Successful Treatment of Early Post-Transplant Bloodstream and Pulmonary Infection Caused by Carbapenem-Resistant Klebsiella pneumoniae With a Combination of CeftazidimeAvibactam and Carbapenem: A Case Report. , 52(9) : 2742-2746.
Munoz-Price LS,Poirel L,Bonomo RA,Schwaber MJ,Daikos GL .2013 .Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. The Lancet Infectious Diseases, 13(9) : 785-796.
Mantilla-Calderon D,Jumat MR,Wang T,Ganesan P,AlJassim N .2016 .Isolation and Characterization of NDMPositive Escherichia coli from Municipal Wastewater in Jeddah, Saudi Arabia. Antimicrobial Agents and Chemotherapy, 60(9) : 5223-5231.
Bush K,Jacoby GA .2010 .Updated functional classification of β- lactamases. Antimicrobial Agents and Chemotherapy, 54(3) : 969-976.
Agents Antimicrobial .2018 .. , 62(10) : e01076-18.
Bush K. .2015 .A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. International Journal of Antimicrobial Agents, 46(5) : 483-493.
Kazmierczak KM,Bradford PA,Stone GG,de Jonge BLM,Sahm DF BLM .2015 .In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from. , : .
Agents Antimicrobial .2018 .. , 62(12) : e00592-18.
Davido B,Fellous L,Lawrence C,Maxime V,Rottman M .2017 .Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo- β-Lactam resistance conferred by metallo-β- lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 61(9) : e01008-17.
Marshall S,Hujer AM,Rojas LJ,Papp-Wallace KM,Humphries RM .2017 .Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? Antimicrobial Agents. , 61(4) : e02243-16.
Bocanegra-Ibarias P,Camacho-Ortiz A,Garza-González E,Flores-Treviño S,Kim H .2020 .Aztreonam plus ceftazidimeavibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy. Journal of Global Antimicrobial Resistance, 23 : 417-419.
Rosa R,Rudin SD,Rojas LJ,Perez-Cardona A,Aragon L .2017 .Application of "Precision Medicine" Through the Molecular Characterization of Extensively Drug-Resistant Klebsiella pneumoniae in a Multivisceral Transplant Patient. Clinical Infectious Diseases, 65(4) : 701-702.
Pragasam AK,Veeraraghavan B,Shankar BA,Bakthavatchalam YD,Mathuram A .2019 .Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from In vitro study. Indian journal of medical microbiology, 37(1) : 34-41.
Zhang W,Guo Y,Li J,Zhang Y,Yang Y .2018 .In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae. Antimicrobial Resistance and Infection Control, 7 : 142.
Emeraud C,Escaut L,Boucly A,Fortineau N,Bonnin RA .2019 .Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-LactamaseProducing Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 63(5) : e00010-19.
Wayne PA,Logan LK,Bonomo RA .2016 .; 3(2): ofw090.. , 294 : .
Padhi S .2011 .New Delhi metallo-beta-lactamase: a weapon for the newly emerging drug-resistant bacteria. Indian Journal of Medical Sciences, 65(8) : 317-320.
Balkhy HH,El-Saed A,Alshamrani MM,Alsaedi A,Al Nasser W .2020 .Antimicrobial Resistance and Infection Control, (. , 9(1) : 1-12.
Alghoribi MF,Binkhamis K,Alswaji AA,Alhijji A,Alsharidi A .2020 .Genomic analysis of the first KPC-producing Klebsiella pneumoniae isolated from a patient in Riyadh: A new public health concern in Saudi Arabia. Journal of Infection and Public Health, 13(4) : 647-650.
Hala S,Antony CP,Alshehri M,Althaqafi AO,Alsaedi A .2019 .First report of Klebsiella quasipneumoniae harboring bla (KPC-2) in Saudi Arabia. Antimicrobial Resistance and Infection Control, 8 : 1-8.
van Duin D,Doi Y. .2017 .The global epidemiology of carbapenemase-producing Enterobacteriaceae. , 8(4) : 460-469.
Karakonstantis S,Kritsotakis EI,Gikas A .2020 .Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options. Journal of Antimicrobial Chemotherapy, 75(2) : 271-282.
Falcone M,Daikos GL,Tiseo G,Bassoulis D,Giordano C .2021 .Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β- lactamase-Producing Enterobacterales. Clinical infectious diseases. , 72(11) : 1871-1878.
Tamma PD,Aitken SL,Bonomo RA,Mathers AJ,van Duin D .2023 .Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clinical infectious diseases. Infectious Diseases Society of America, : ciad428.
de Jonge BL,Karlowsky JA,Kazmierczak KM,Biedenbach DJ,Sahm DF .2016 .In Vitro Susceptibility to CeftazidimeAvibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (. Antimicrobial Agents and Chemotherapy, 60(5) : 3163-3169.
Agents Antimicrobial .2015 .. , 59(3) : 1789-1793.
Agents Antimicrobial .2016 .. , 60(6) : 3601-3607.
Hellmark B,Unemo M,Nilsdotter-Augustinsson A,Söderquist B. .2010 .In vitro antimicrobial synergy testing of coagulase-negative staphylococci isolated from prosthetic joint infections using Etest and with a focus on rifampicin and linezolid. European Journal of Clinical Microbiology & Infectious Diseases, 29 : 591-595.
.2017 .Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gramnegative pathogens. Diagnostic Microbiology and Infectious Disease, 88(4) : 352-354.
. .To read the copy of this license please visit: https://creativecommons. , : .
0

Citations

0

Downloads

43

Views